Search results
Your search for process/pmg6 returned no results
Showing 916 to 930 of 2854 results for process
Showing 916 to 930 of 2854 results for process
Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]
In development Reference number: GID-TA11553 Expected publication date: TBC
Awaiting development Reference number: GID-TA11624 Expected publication date: TBC
In development Reference number: GID-TAG525 Expected publication date: TBC
In development Reference number: GID-HST10067 Expected publication date: 19 August 2026
Information and benefits about shared decision making. Includes links to patient decision aids.
Fees for technology appraisals and highly specialised technologies
NICE fees for technology appraisals and highly specialised technologies
This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life. It aims to improve end of life care for people in their last days of life by communicating respectfully and involving them, and the people important to them, in decisions and by maintaining their comfort and dignity. The guideline covers how to manage common symptoms without causing unacceptable side effects and maintain hydration in the last days of life.
This guideline covers medicines adherence in people aged 18 and over. It recommends how to encourage adherence to medicines by supporting and involving people in decisions about their prescribed medicines. It aims to ensure that a person’s decision to use a medicine is an informed choice.
schemes approved as part of a NICE appraisal (Excel) . The proposal review process Complex schemes Complex schemes include:...
This quality standard covers interventions to maintain and improve the mental wellbeing and independence of people aged 65 or older, and how to identify those at risk of a decline. It describes high-quality care in priority areas for improvement. It does not cover the mental wellbeing and independence of people who live in a care home or attend one on a day-only basis.
In development Reference number: GID-HTG10176 Expected publication date: TBC
The principles that guide the development of NICE guidance and standards.
In development Reference number: GID-TA11817 Expected publication date: 09 July 2026
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
In development Reference number: GID-TA10024 Expected publication date: 28 June 2017
We are listening to your views on this Technology appraisal guidance. Comments close 11 May 2026.